Fiscal Year Ending March 2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)

Summary of Business Performance

For the nine-month period ended December 31, 2025 (April 1, 2025 to December 31, 2025), net sales amounted to 18,466 million yen (6.5% increase YoY), operating income was 3,657 million yen (0.8% increase YoY), ordinary income totaled 3,796 million yen (2.6% increase YoY), and net income attributable to owners of parent was 2,236 million yen (3.8% increase YoY). This growth was mainly driven by increased sales in artificial dialysis products, intravenous catheters, and intervention products.

Summary of Financial Position

Total assets were 51,947 million yen, a 1.0% decrease compared to the same period last year, while net assets increased by 1.0% to 45,605 million yen, and the equity ratio stood at 87.8%, maintaining financial soundness. The decrease in current assets was due to a decline in cash and deposits, with fixed assets remaining virtually unchanged.

Dividend Status

The annual dividend forecast for the fiscal year ending March 2026 is 100 yen (a 10 yen increase YoY), with an interim dividend of 50 yen already paid at the end of the second quarter. There are no revisions to the latest dividend forecast.

Full-year Consolidated Earnings Guidance

For the full fiscal year ending March 2026, the consolidated earnings guidance forecasts net sales of 24,000 million yen (6.4% increase YoY), operating income of 4,500 million yen (0.3% increase YoY), ordinary income of 4,592 million yen (1.4% decrease YoY), net income attributable to owners of parent of 2,924 million yen (3.0% decrease YoY), and earnings per share of 200.75 yen. There are no changes to the latest earnings guidance.